Search TGA

Safety information Home

Consumers

Health professionals Industry

About the TGA

News room

**News room** 

News & public notices

Latest news & updates

Media releases & statements

Behind the news

Newsletters & articles

Subscribe to updates

TGA tenders

TGA laboratory testing reports

- Consultations & reviews
- Events, training & presentations
- Blog

Home » News room » News & public notices » Media releases & statements

**A- A+ ♣ >** Share

# TGA approves name change of COVID-19 Vaccine AstraZeneca to VAXZEVRIA

19 August 2021

The Therapeutic Goods Administration (TGA), part of the Department of Health, has approved AstraZeneca's submission to change the name of its COVID-19 Vaccine AstraZeneca to VAXZEVRIA.

The name is now consistent with that used overseas, including in the European Union and Canada. This is expected to alleviate confusion and further clarify that the vaccine produced by CSL and Seqirus in Melbourne is the same as that produced internationally. This name change will also help facilitate international recognition for Australians who have been vaccinated with the AstraZeneca vaccine.

Importantly, this is the only change to the vaccine. All other aspects, such as manufacturing and quality control, are unchanged and align with the way the vaccine is produced in other jurisdictions. Top of page

At this stage, it is estimated that supply in Australia of the VAXZEVRIA-branded product will commence in late 2021. Unce supply or the vaccine commences under the new name, the vaccine will no longer be supplied under the original name. Some stock with the original name may still be in use after the name change.

Contact for members of the media:

- Email: news@health.gov.au ☑
- Phone: 02 6289 7400

**Category:** Prescription medicines **Tags:** COVID-19 vaccines

**URL:** https://www.tga.gov.au/node/939104

Copyright Privacy Disclaimer Security Acronyms & glossary Sitemap A-Z guide Contact the TGA Freedom of Information

### **Safety information**

Report a problem or side effect

Alerts

Recalls

Prescription opioids

Medicine shortages

Early warning system

Black Triangle Scheme

Safety information & education

COVID-19

COVID-19 treatments

COVID-19 vaccines

# Industry

**SME** Assist

Regulation basics

Advertising therapeutic goods

Prescription medicines

Over-the-counter medicines

Complementary medicines

Sunscreens

Medical devices & IVDs

Biologicals

Blood and blood components

Other therapeutic goods

Manufacturing therapeutic goods Scheduling of medicines & poisons

#### **Consumers**

Report a problem or side effect

Travelling with medicines and medical devices

Buying medicines and medical devices online

Can I import it?

Medicines Medical devices

Advertising hub

Consumer information & education

# **Health professionals**

Report a problem or side effect

Accessing unapproved products

Advertising

Medicines

Medical devices

Biologicals

Safety information

Other resources

Health professional information & education

## **About the TGA**

TGA basics

Contact the TGA

**Educational materials** 

Compliance and enforcement hub

Regulatory decisions & notices

Committees

Employment & job vacancies

Fees and payments

International

TGA Internet site archive

TGA Business Services

### **News room**

News & public notices

Consultations & reviews Events, training & presentations

Blog

www.australia.gov.au <sup>데</sup> www.health.gov.au <sup>데</sup> www.odc.gov.au <sup>데</sup>